UpToDate: New-onset urticaria
New-onset urticaria


Riccardo Asero, MD
Section Editors:
Sarbjit Saini, MD
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor:
Anna M Feldweg, MD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jun 2019. | This topic last updated: Oct 16, 2017.

INTRODUCTIONUrticaria, or hives (sometimes referred to as welts or wheals), is a common disorder, with a prevalence of approximately 20 percent in the general population [1]. A typical urticarial lesion is an intensely pruritic, erythematous plaque (picture 1).


Urticaria is sometimes accompanied by angioedema, which is swelling deeper in the skin. A presumptive trigger, such as a drug, food ingestion, insect sting, or infection, may be identifiable in patients with new-onset urticaria, although no specific cause is found in many cases, particularly when the condition persists for weeks or months. (See ‘Etiologies’ below.)

The epidemiology, clinical manifestations, etiologies, diagnosis, and management of new-onset urticaria will be reviewed here. Chronic urticaria and isolated angioedema are discussed separately. (See «Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history» and «Chronic spontaneous urticaria: Standard management and patient education» and «An overview of angioedema: Clinical features, diagnosis, and management».)

CATEGORIZATION OF URTICARIAUrticaria (with or without angioedema) is commonly categorized by its chronicity:

Acute urticaria — Urticaria is considered acute when it has been present for less than six weeks.

Chronic urticaria — Urticaria is considered chronic when it is recurrent, with signs and symptoms recurring most days of the week, for six weeks or longer.

The period of six weeks is somewhat arbitrary and simply represents a timeframe in which new cases of urticaria usually resolve. More than two-thirds of cases of new-onset urticaria prove to be self-limited (acute) [2]. The lesions of acute and chronic urticaria are identical in appearance, so when the problem first develops, it is not possible to differentiate the two disorders [3].

EPIDEMIOLOGYUrticaria affects up to 20 percent of the population at some point in their lives and occurs across the age spectrum [1].

CLINICAL MANIFESTATIONSUrticarial lesions are circumscribed, raised, erythematous plaques, often with central pallor (picture 2). Lesions may be round, oval, or serpiginous in shape and vary in size from less than 1 centimeter to several centimeters in diameter. They are intensely itchy. Pruritus may disrupt work, school, or sleep. Symptoms often seem most severe at night.

2. Multiple images of urticaria are shown. Urticarial lesions may be rounded (F) or irregular (A) in shape and uniform or mixed (G) in morphology. Individual lesions may be small (H) or large (D). Urticaria are raised plaques, although they may appear flattened in patients taking antihistamines (C). Although lesions are consistently erythematous, this may be difficult to appreciate on darkly pigmented skin (I). Some urticaria show central clearing (E).

Individual lesions are transient, usually appearing and enlarging over the course of minutes to hours and then disappearing within 24 hours. Lesions may coalesce as they enlarge. Urticarial lesions are not normally painful and resolve without leaving residual ecchymotic marks on the skin, unless there is trauma from scratching. If lesions are long-lasting, painful, or leave residual bruising, the diagnosis of urticarial vasculitis should be considered. (See ‘Differential diagnosis’below.)

Any area of the body may be affected, although areas in which clothing compresses the skin (eg, under waistbands) or skin rubs together (axillae) are sometimes affected more dramatically. Typically, compressed areas become more severely affected once the restricting clothing has been removed.

Angioedema, when associated with urticaria, usually affects the face and lips, extremities, and/or genitals. Angioedema without urticaria should prompt consideration of other angioedema disorders, such as drug-induced angioedema (eg, angiotensin-converting enzyme [ACE] inhibitors), idiopathic angioedema, and hereditary and acquired C1 inhibitor deficiency. (See «ACE inhibitor-induced angioedema» and «An overview of angioedema: Pathogenesis and causes».)

PATHOPHYSIOLOGYUrticaria is mediated by cutaneous mast cells in the superficial dermis. Basophils have also been identified in lesional biopsies [4]. Mast cells and basophils release multiple mediators upon activation including histamine (which causes itching) and vasodilatory mediators (which cause localized swelling in the uppermost layers of the skin). The same process gives rise to angioedema when mast cells deeper in the dermis and subcutaneous tissues are activated. (See «Mast cells: Development, identification, and physiologic roles».)

ETIOLOGIESThe potential causes of new-onset urticaria are numerous, although no specific etiology can be identified in many patients. Acute urticaria is more likely to have an identifiable etiology compared with chronic urticaria. The different etiologies activate mast cells through various mechanisms.

Common causes — Common causes of new-onset urticaria include infections; allergic reactions to medications, foods, or insect stings and bites; reactions to medications that cause nonallergic mast cell activation (eg, narcotics); and ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) (table 1).

Infections — Viral, bacterial, and parasitic infections are associated with new-onset urticaria.

Viral and bacterial infections – Acute urticaria may develop during or following a viral or bacterial infection, particularly in children. Infections are associated with over 80 percent of cases of acute urticaria in some pediatric series [2,5-8]. Immune activation, involving immune complex formation and/or complement activation, is a proposed mechanism, although the exact pathogenesis is unclear.

In one study, common viral illnesses and bacterial infections (eg, urinary tract infections) were the leading identifiable trigger for acute urticaria in 57 children between the ages of one and three years who presented to an emergency department [5]. Many of these children had also received antibiotics, so it was not clear in these patients if the infection, the drug, or the combination had triggered urticaria.

In another study, 88 children presenting to an emergency department with delayed cutaneous reactions while taking beta-lactam antibiotics were evaluated. Of these, 47 of 88 had urticarial eruptions. All were tested for common childhood viral infections and then later evaluated for drug allergy with testing followed by drug challenge (regardless of test results) [9]. Two-thirds had one or more positive viral studies, demonstrating infections with picornavirus (most common), coronavirus, respiratory syncytial virus, and several others. When the children were later challenged with the culprit antibiotic, only 4 had recurrent urticaria. Thus, urticaria was related to the viral infection or the combination of the viral infection and the antibiotic in most, and only 4 of 88 had a drug allergy. (See «Penicillin allergy: Delayed hypersensitivity reactions», section on ‘Delayed urticarial eruptions’.)

Acute urticaria, refractory to antihistamines but responsive to azithromycin, has been associated with documented Mycoplasma pneumoniae infection in children [10,11].

Acute urticaria can occur in the prodromic, preicteric phase of hepatitis A or B infection and less commonly with hepatitis C [12]. Urticaria may be an initial manifestation of human immunodeficiency virus (HIV) infection [13]. (See «Acute and early HIV infection: Pathogenesis and epidemiology».)

Parasitic infections – Parasitic infections generally cause acute, self-limited urticaria in association with prominent eosinophilia [14].

Infections with AncylostomaStrongyloidesFilariaEchinococcusTrichinellaToxocaraFasciolaSchistosoma mansoni, and Blastocystis hominis have all been associated with urticaria. Stool examination is probably only indicated in travelers to endemic areas and in patients with peripheral blood eosinophilia. (See «Approach to the patient with unexplained eosinophilia».)

Ingestion of fish contaminated with the parasite Anisakis simplex can also cause urticaria. Anisakis can be transmitted through the ingestion of sushi [15]. (See «Seafood allergies: Fish and shellfish», section on ‘Anisakis’.)

IgE-mediated allergic reactions — Immunoglobulin E (IgE)-mediated, type I immediate allergic reactions often involve urticaria. Urticaria that is caused by an allergic reaction usually occurs within minutes to two hours of exposure to the culprit allergen. Causes include medications, foods and food additives, insect stings and bites, latex, and blood products.

Allergic reactions may be limited to the skin or part of a systemic allergic reaction (eg, anaphylaxis) (table 2 and table 3). Generalized urticaria or angioedema following exposure to a potential allergen should be interpreted as a systemic reaction with an attendant risk of anaphylaxis upon subsequent exposure, and patients should be advised to avoid the potential cause until further evaluated. (See ‘Referral’ below.)

Medications – The antibiotics most frequently implicated in causing IgE-mediated urticaria include beta-lactams (penicillins and cephalosporins), although antibiotics from virtually all classes have been reported (picture 3). (See «Penicillin allergy: Immediate reactions».)

Stinging and biting insects – Stinging insects that can cause true urticarial lesions as part of an allergic reaction include Hymenoptera (eg, bees, wasps, hornets, and imported fire ants) and Triatoma (eg, kissing bugs).

Bedbugs, fleas, and mites can cause papular urticaria, usually on the lower extremities. The lesions of papular urticaria resolve over the course of weeks. (See «Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management» and «Reactions to bites from kissing bugs (primarily genus Triatoma)» and «Bedbugs».)

Latex – Occupational, recreational, dental, or surgical exposure to latex may cause urticaria, angioedema, asthma, or anaphylaxis in susceptible individuals [16]. Everyday scenarios in which patients may be exposed to significant amounts of latex include inflation of balloons and use of latex gloves. Penile and vulvar/vaginal urticaria and angioedema are seen upon exposure to latex condoms, with vulvar/vaginal symptoms resembling acute vaginitis. (See «Latex allergy: Epidemiology, clinical manifestations, and diagnosis».)

Foods and certain food additives – Allergic reactions to foods can cause urticaria, typically within 30 minutes of ingestion. Milk, eggs, peanuts, tree nuts, soy, and wheat are the most common foods to cause generalized urticaria in children. In adults, fish, shellfish, tree nuts, and peanuts are most often implicated [17]. In Mediterranean areas, the most frequent cause of food-induced urticaria is the peach, due to sensitization to lipid transfer protein [18]. (See «Clinical manifestations of food allergy: An overview».)

Synthetic additives in commercially prepared foods are believed to be a relatively rare cause of urticarial reactions. In contrast, certain natural compounds, such as the yellow food dye annatto and the red dye carmine red, have been well-documented causes of urticaria and anaphylaxis. Adverse reactions to food additives are discussed in detail elsewhere. (See «Allergic and asthmatic reactions to food additives».)

Contact with allergens – Physical contact with a number of agents may result in urticaria, including plant products and resins, raw fruits and vegetables, or raw seafood. People employed in food processing can develop contact urticaria from various exposures [19]. Children sometimes develop urticaria upon contact with animal saliva, if allergic to those allergens. In contrast, detergents, soaps, and lotions are more likely to cause contact dermatitis than urticaria. (See «Clinical features and diagnosis of allergic contact dermatitis» and «Contact dermatitis in children».)

Urticarial transfusion reactions – Acute urticaria in the setting of transfusion may arise from several mechanisms, including IgE-mediated allergic reactions, complement-mediated reactions, and other immunologic events. These reactions are discussed elsewhere. (See «Immunologic transfusion reactions».)

Direct mast cell activation — Certain drugs, foods, and plants can cause urticaria due to mast cell degranulation through a non-IgE-mediated mechanism. The most frequently implicated are narcotics, muscle relaxants, vancomycin, and radiocontrast media. Some berries and nettle plants are examples of plants and plant foods that cause direct mast cell activation.

Narcotics – Opiate analgesics, such as morphine and codeine, cause direct mast cell activation. Dextromethorphan, an opiate derivative ingredient in cough suppressant syrups, can also cause urticaria [20].

Muscle relaxants – Anesthetic muscle relaxants, including atracuriumvecuroniumsuccinylcholine, and curare, may cause urticaria. Muscle relaxants can also cause IgE-mediated anaphylaxis. Allergic reactions to these medications are reviewed in greater detail elsewhere. (See «Perioperative anaphylaxis: Clinical manifestations, etiology, and management».)

Vancomycin – The «red man» syndrome is seen after rapid vancomycin infusion and presents as diffuse erythema or flushing, sometimes with accompanying urticaria. The concomitant use of opiates and vancomycin may increase the likelihood of a reaction. (See «Vancomycin hypersensitivity».)

Radiocontrast medium – Radiocontrast agents are associated with urticaria and angioedema. (See «Diagnosis and treatment of an acute reaction to a radiologic contrast agent».)

Certain foods – Tomatoes, strawberries, and a small number of other foods can cause generalized urticaria or contact urticaria through nonimmunologic mechanisms, particularly in young children [6]. These foods are sometimes referred to as «pseudoallergens.» IgE-mediated allergies to these foods are also possible.

Stinging nettle – The nettle plant (Urtica dioica), after which the disorder «urticaria» was named, is a common weed found in Europe, North and South America, and parts of Africa that causes hives and a stinging sensation immediately following contact with the skin [21-23]. These symptoms may be due to histamine in the nettle plant itself, in addition to mediators that cause pain [24].

Nonsteroidal anti-inflammatory drugs — Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirinibuprofennaproxen sodium, and others, can trigger urticaria and/or angioedema by two distinct mechanisms:

Pseudoallergic/pharmacologic – NSAIDs cause urticaria in some individuals, presumably due to underlying abnormalities in arachidonic acid metabolism. This form of NSAID reaction is called a pseudoallergic reaction because the mechanism is nonimmunologic. NSAID pseudoallergy can be seen with any agent (eg, aspirinibuprofen) that inhibits the cyclooxygenase-1 (COX-1) enzyme and rarely occurs with agents that are very weak inhibitors of COX-1. Patients with pseudoallergy usually tolerate acetaminophen and the selective cyclooxygenase-2 (COX-2) inhibitors. Pseudoallergic reactions attributed to NSAIDs are discussed in more detail separately. (See «NSAIDs (including aspirin): Allergic and pseudoallergic reactions», section on ‘Pseudoallergic reactions’.)

Allergic – A specific NSAID can also cause acute urticaria in patients who are allergic to that one agent. These reactions are presumed to represent true, immunologic allergy. (See «NSAIDs (including aspirin): Allergic and pseudoallergic reactions», section on ‘Allergic reactions (presumed IgE-mediated)’.)

Both pharmacologic and allergic reactions to NSAIDs can be severe. However, the management differs. (See «NSAIDs (including aspirin): Allergic and pseudoallergic reactions», section on ‘Management’.)

Uncommon causes — Uncommon causes of new-onset urticaria include various physical factors, serum sickness, and hormone-associated disorders.

Physical stimuli – Physical urticarial syndromes are forms of chronic urticaria that are triggered by specific physical factors, such as cold exposure, sudden changes in body temperature, pressure or vibration against the skin, exercise, exposure to sunlight, or other stimuli. These disorders are reviewed separately. (See «Physical (inducible) forms of urticaria» and «Cold urticaria».)

Serum sickness – Serum sickness and serum sickness-like reactions to exogenous proteins or medications may present with an urticarial rash accompanied by fever, polyarthralgias, polyarthritis, and/or lymphadenopathy. This typically develops within one to three weeks after administration of the causative agent. Proteinuria, edema, and abdominal pain may also be present. These reactions are discussed elsewhere. (See «Serum sickness and serum sickness-like reactions».)

Progesterone-associated urticaria – There are rare reports of progesterone-containing oral contraceptives, hormone replacement therapy, or endogenous progesterone associated with cyclic urticaria [25,26]. The disorder is sometimes called autoimmune progesterone dermatitis [27-30]. Lesions usually appear during the second half of the menstrual cycle and resolve with menstruation.

SYSTEMIC DISORDERS THAT MAY INCLUDE URTICARIAUncommonly, urticaria or urticaria-like lesions may be an early feature of a systemic disorder, including the following:

Urticarial vasculitis – Urticarial vasculitis should be suspected when individual lesions are painful, are long-lasting (longer than 24 to 36 hours), appear purpuric or ecchymotic, or leave residual ecchymosis or hyperpigmentation upon resolution (in the absence of trauma from scratching) (picture 4 and picture 5 and picture 6). Vasculitis should also be suspected in patients with urticaria accompanied by fever, arthralgias, arthritis, weight changes, bone pain, or lymphadenopathy. Urticarial vasculitis may be a cutaneous or systemic disease, and it may occur in the setting of another rheumatologic disorder or rarely, a malignancy. (See «Urticarial vasculitis» and «Cutaneous manifestations of internal malignancy».)

4. Urticarial patch with central ecchymosis.

Mastocytosis – Mastocytosis and mast cell disorders are rare conditions in which patients present with apparent allergic reactions and anaphylaxis to a variety of triggers. Characteristic skin findings are helpful in diagnosis. These disorders are reviewed separately. (See «Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations».)

Systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, celiac disease, autoimmune thyroid disease, and other autoimmune diseases – Urticaria may be a presenting manifestation or occur sporadically over time in patients with autoimmune conditions [31]. The etiology of this remains unclear but may be due to direct mast cell activation via complement receptors or due to the generation of autoantibodies that may result in anaphylactoid degranulation. Screening for these disorders in the setting of an acute episode of urticaria is not indicated, unless there are other preceding symptoms that suggest that one of these disorders may be present.

5. Annular patch with elevated borders.

Cutaneous small vessel vasculitis – Some forms of cutaneous small vessel vasculitis can appear urticarial during early stages. Urticarial lesions that are persistent in a single location for >24 hours, have bruising, are painful, or are accompanied by systemic symptoms (eg, fever) should raise a concern for vasculitis.

Urticarial vasculitis is a disorder characterized by urticarial lesions with vasculitic findings on skin biopsy (picture 5). The disorder may be systemic or limited to the skin. (See «Urticarial vasculitis».)

Immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) is a systemic vasculitis with a prominent cutaneous component characterized by purpuric lesions, particularly involving the lower extremities. The skin lesions can be urticarial initially, although the development of systemic disease with arthralgias, abdominal pain, and renal involvement should prompt investigation for this condition. (See «IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis», section on ‘Skin manifestations’.)

Discrete and confluent urticarial patches with unusual annular and semi-annular features.

Patients with lupus may also develop urticarial lesions that persist and become vasculitic. Skin biopsy may show evidence of vasculitis. (See «Overview of cutaneous lupus erythematosus».)

Malignancies – Urticaria may also be seen with malignancies, especially immunoglobulin M (IgM) and sometimes immunoglobulin G (IgG) paraproteinemias. The etiology is also unclear but may be due to complement-mediated pathways. In these cases, the urticaria is persistent and becomes chronic. (See «Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history», section on ‘Unclear association with malignancy’.)

The urticaria associated with systemic disorders is usually recurrent, persistent, and relatively difficult to treat, so patients with these disorders typically present with chronic urticaria. Clinical features that can help distinguish these disorders from uncomplicated chronic urticaria are reviewed separately. (See «Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history», section on ‘Differential diagnosis’.)

EVALUATION AND DIAGNOSISUrticaria is diagnosed clinically, based upon a detailed history and physical examination confirming the presence of characteristic skin lesions [32-35].

Clinical history — The clinical history should determine the following:

Were there other signs and symptoms of a generalized allergic reaction or anaphylaxis? Patients may fail to report more subtle symptoms unless specifically asked. The clinician should ask about chest tightness or difficulty breathing, hoarse voice or throat tightness, nausea, vomiting, crampy abdominal pain, lightheadedness, and other symptoms of anaphylaxis (table 2). (See «Anaphylaxis: Emergency treatment».)

Has the patient had hives previously in the past? Some children develop acute urticaria repeatedly with infections. Adults may develop urticaria following nonsteroidal anti-inflammatory drug (NSAID) ingestion but may not recognize the association until it has occurred several times. Does the patient have other allergic disorders?

Were there any symptoms or signs to suggest an underlying systemic disorder? Specifically, has the patient recently had unexplained fever, weight loss, arthralgias, arthritis, or bone pain [36,37]? Diseases that may include hives as part of the clinical presentation are reviewed separately. (See ‘Systemic disorders that may include urticaria’ above.)

Is a possible etiology apparent from the patient’s history (table 1)? (See ‘Etiologies’ above.)

Was the patient in his/her usual state of health when the hives appeared or has the patient been ill recently with viral or bacterial infections? Has the patient experienced any recent health events, such as musculoskeletal injuries for which he/she was taking NSAIDs or new diagnoses requiring unfamiliar medications or treatments?

The patient should be asked to review events in the hours before the urticaria appeared. What had the patient ingested (foods, beverages, candy)? Was the patient involved in exercise or physical exertion? Was the patient exposed to extremes of temperature or stung by an insect? The answers may reveal clues to allergic or physical causes of urticaria.

Patients should be questioned about any new medications or supplements in the preceding days or weeks [38,39]. Were any medications taken in the hours before the urticaria appeared?

Inquiries should be made about recent travel (and symptoms of parasitic infection) and sexual history. (See ‘Infections’ above.)

A complete review of systems is valuable in the patient with new-onset urticaria.

Physical examination — Lesions should be visualized directly in order to make the diagnosis with certainty, since the term «hives» is used nonspecifically by patients. If the patient has no lesions at the time of evaluation, showing patients photographs of urticaria and asking if their lesions look similar can be helpful, although the diagnosis will need to be confirmed at some point in the future (picture 2).


Multiple images of urticaria are shown. Urticarial lesions may be rounded (F) or irregular (A) in shape and uniform or mixed (G) in morphology. Individual lesions may be small (H) or large (D). Urticaria are raised plaques, although they may appear flattened in patients taking antihistamines (C). Although lesions are consistently erythematous, this may be difficult to appreciate on darkly pigmented skin (I). Some urticaria show central clearing (E).

Individual urticarial lesions usually appear and resolve completely within 24 hours. If the patient is unsure of the duration of the lesions, a lesion can be circled with a pen and time to resolution noted.

Laboratory studies — Laboratory studies are typically normal in patients who lack any history or physical findings to suggest an underlying disease process [3].

For patients presenting with new-onset urticaria (with or without angioedema) in whom the clinical history and physical exam do not suggest an underlying disorder or urticarial vasculitis, international, European, and British practice parameters state that laboratory testing is not indicated [40-42]. American practice parameters state that a limited evaluation «may be considered» in such patients, primarily for the purpose of detecting underlying disorders earlier in the one-third of patients in whom urticaria will prove persistent (ie, initial presentation of chronic urticaria) [43]. In this setting, complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests are suggested. However, the author’s approach is to obtain these tests in patients with persistent symptoms.

In patients in whom a specific etiology is suspected, laboratory studies and further evaluation should be directed at establishing or excluding that cause. (See ‘Etiologies’ above.)

Tests for allergic causes — An allergic cause is possible if the clinical history reveals a specific trigger to which the patient was exposed shortly before the onset of symptoms (usually within one to two hours). If the history does suggest a possible allergy, serum tests for allergen-specific immunoglobulin E (IgE) antibodies are appropriate, if commercially available. For example, if a patient who does not normally eat seafood but did so at a special occasion develops hives within 10 minutes of eating a crab cake, it would be reasonable to obtain a crab-specific IgE test, particularly if there were no other new foods ingested and the patient is avoiding seafood for fear of a repeat reaction. However, the interpretation of allergy tests can require some expertise. A positive result is suggestive, although not diagnostic, of allergy, and a negative result does not exclude allergy. Because of this, we suggest that patients suspected of having an allergy be referred to an allergist/immunologist for further evaluation when possible. Skin tests with fresh food, which should be performed by an allergy specialist, is probably the most convenient, inexpensive, and sensitive way to detect food hypersensitivity. (See ‘Referral’ below and «Overview of in vitro allergy tests».)

DIFFERENTIAL DIAGNOSISThe conditions discussed in this section are those that may mimic various features of urticaria [44]. The presence or absence of pruritus is a helpful clinical feature that can be used to narrow the differential.

Nonpruritic conditions — Nonpruritic conditions that may resemble acute urticaria include viral exanthems, the skin changes of auriculotemporal syndrome, and Sweet syndrome.

Viral exanthems – Viral exanthems are common in children and can occur with many different infections, including erythema infectiosum (fifth disease), Epstein-Barr virus, enteroviruses, and measles. However, viral exanthems are generally not pruritic and usually consist of erythematous maculopapular eruptions that persist for days. Fever is often present. The macules are relatively fixed compared with urticarial lesions, which continually change, with new lesions appearing as older lesions resolve. (See topic reviews on specific infections.)

Auriculotemporal syndrome – Auriculotemporal syndrome is a nonpruritic flushing and/or sweating of the skin over the cheeks or jawline (the areas supplied by the auriculotemporal nerve) that occurs transiently after eating and may be mistaken for urticaria associated with food allergy [45]. It can be seen in children or adults and may develop following damage to the nerve secondary to forceps delivery, viral infection, surgery, or other local trauma. Unilateral distribution is typical, although bilateral cases have been reported [46].

Sweet syndrome – Sweet syndrome is an uncommon disease characterized by recurrent episodes of painful, long-lasting inflammatory papules and plaques associated with fever, arthralgias, and peripheral leukocytosis. There may be a history of a febrile illness one to three weeks before the onset of skin lesions in some cases. (See «Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis».)

Pruritic conditions — Pruritic conditions that are more likely to be confused with urticaria are discussed here. An overview of the causes of pruritic dermatoses is found separately. (See «Pruritus: Etiology and patient evaluation».)

Atopic dermatitis – Atopic dermatitis is a common disorder that presents initially as intensely pruritic erythematous patches with papules and some scaling. In children, the face, scalp, extremities, or trunk are typically involved, while the diaper area is spared. In older children and adults, the flexural areas (neck, antecubital fossae, and popliteal fossae) are most commonly involved. Other sites include the face, wrists, and forearms (picture 7). Erythematous areas of involvement last for days or weeks and have ill-defined borders. Scaling and xerosis develop with time. (See «Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis».)

7. Severe atopic dermatitis in a 12-year-old girl showing in the typical location of the popliteal fossae. Note the oozing of serous fluid from the most involved areas, plus the papular component and erythema.

Contact dermatitis – Contact dermatitis refers to any dermatitis arising from direct skin exposure to a substance. The dermatitis may either be allergic or irritant-induced. The latter is more common. Contact dermatitis is an erythematous, papular dermatitis, often with areas of vesiculation (picture

8. Allergic contact dermatitis is characterized by an erythematous, papular dermatitis with indistinct margins, distributed in areas of exposure.

8). It is distributed in the areas of direct contact. (See «Contact dermatitis in children» and «Irritant contact dermatitis in adults» and «Common allergens in allergic contact dermatitis».)

Drug eruptions – Drug eruptions, also called morbilliform or exanthematous drug eruptions, are cutaneous drug reactions that closely mimic viral exanthems but occur in association with a medication. These dermatoses may or may not be pruritic and begin as small macules and/or papules that become larger and confluent with time (picture 9). The individual lesions are persistent, unlike urticaria. (See «Drug eruptions».)

9. Drug-induced exanthems, such as this morbilliform eruption, often begin in dependent areas and generalize.

Insect bites – Insect bites produce individual lesions that persist for days in most cases (see «Insect bites»). However, the stings of some insects can cause true urticaria as part of a systemic allergic reaction. (See ‘IgE-mediated allergic reactions’ above.)

Bullous pemphigoid – In older adults, bullous pemphigoid may start with pruritus, with or without urticarial lesions. Blistering usually becomes evident eventually. (See «Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid», section on ‘Bullous pemphigoid’.)

Erythema multiforme minor – Erythema multiforme minor is a syndrome characterized by erythematous, iris-shaped macules and vesiculobullous lesions with a target appearance (picture 10). The lesions may be painful or pruritic and distributed symmetrically on the extensor surfaces of the extremities (particularly the palms and soles). Individual lesions last several days, unlike urticaria. There may be accompanying fever and malaise. (See «Erythema multiforme: Pathogenesis, clinical features, and diagnosis».)

10. Characteristic target lesions of the palm in erythema multiforme begin with a central vesicle.

Plant-induced reactions – Poison ivy and poison oak can present with urticaria-like lesions initially that evolve into vesicular lesions. (See «Poison ivy (Toxicodendron) dermatitis».)

TREATMENTInitial treatment of new-onset urticaria (with or without angioedema) should focus on the short-term relief of pruritus and angioedema, if present. Approximately two-thirds of cases of new-onset urticaria will be self-limited and resolve spontaneously. The literature on management of acute urticaria is sparse, probably because the condition is so often self-limited [47]. The agents discussed below have mostly been evaluated in the treatment of chronic urticaria, and in some cases, their use in acute urticaria is extrapolated from those studies, which are presented separately. (See «Chronic spontaneous urticaria: Standard management and patient education».)

H1 antihistamines — H1 antihistamines may be divided into older, first-generation agents (eg, diphenhydraminechlorpheniraminehydroxyzine) and newer, second-generation agents (eg, cetirizineloratadinefexofenadine, others). Second-generation agents are preferred for both adults and children.

Second-generation agents — The newer, second-generation H1 antihistamines are recommended as first-line therapy by published guidelines from both allergy and dermatology expert panels [48,49]. These drugs are minimally sedating, are essentially free of the anticholinergic effects that can complicate use of first-generation agents, have few significant drug-drug interactions, and require less frequent dosing compared with first-generation agents [50-54]. We know of no data demonstrating that any specific agent is more effective than another for the treatment of acute urticaria, although a few studies in patients with chronic urticaria suggest that cetirizine and levocetirizine may be modestly more effective than other agents. (See «Chronic spontaneous urticaria: Standard management and patient education», section on ‘Agents and efficacy studies’.)

Some patients require higher than standard doses (shown below in parentheses) for control of urticarial symptoms and may experience drowsiness at these higher doses. Caution is therefore warranted until effects upon the individual are understood. The higher doses may have better efficacy in some adults, although this has not been conclusively demonstrated. Studies of higher-dose antihistamines for chronic urticaria are reviewed elsewhere. (See «Chronic spontaneous urticaria: Standard management and patient education», section on ‘H1 antihistamines’.)

Treatment with H1 antihistamines results in clearance of the lesions in some patients, but in others, treatment may only achieve flattening of the lesions and reduction in pruritus, with persistence of erythematous macules. Patients in the latter group can begin to reduce medications after the erythematous lesions clear.

Second-generation H1 antihistamines are only available in oral formulations and include the following:

Cetirizine – Cetirizine demonstrates a rapid onset of action and some mast cell-stabilizing activity. It can be mildly sedating, in a dose-dependent manner, although less so than first-generation agents. The standard dose of 10 mg once daily is appropriate for adults and children aged six years and older (and may be increased to 10 mg twice daily in adults if needed).

The usual dose for children aged two to five years is 5 mg once daily. Smaller children aged six months to two years may be given 2.5 mg once daily (can be increased to 2.5 mg twice daily in children one year and older if needed). The maintenance dose for patients with significant renal and/or hepatic insufficiency should be reduced by one-half.

Levocetirizine – Levocetirizine is an active enantiomer of cetirizine that produces effects equivalent to cetirizine at about one-half of the dose. For adults and children 12 years and older, the standard dose is 5 mg once daily in the evening (or up to 5 mg twice daily in adults if needed) or 2.5 mg once daily in the evening for children aged 6 to 11 years. Levocetirizine is unlikely to be effective as an alternative for patients who did not have an adequate response to cetirizine, and its sedative effects are similar to those of other second-generation antihistamines [55]. Dose reductions are necessary in renal insufficiency.

Loratadine – Loratadine is a long-acting, selective H1 antihistamine. The standard dose is 10 mg once daily for ages six years and older, which is minimally sedating. It can be increased up to 10 mg twice daily in adults if needed. For children aged two to five years, the usual dose is 5 mg once daily. For patients with significant renal and/or hepatic insufficiency, the usual dose is administered every other day.

Desloratadine – Desloratadine is the major active metabolite of loratadine and produces effects equivalent to loratadine at about one-half the dose. For adults and children 12 years and older, the standard dose is 5 mg once daily (or up to 5 mg twice daily in adults if needed).

For children aged 6 to 11 years, the dose is 2.5 mg once daily, and for those aged 1 to 5 years, the dose is 1.25 mg once daily. A lower dose of 1 mg once daily is approved in the United States for small children aged 6 months to 1 year. For patients with significant renal and/or hepatic insufficiency, the usual dose is administered every other day.

Fexofenadine – Fexofenadine is minimally sedating. The suggested dose is 180 mg daily for ages 12 years and older (or up to twice daily in adults if needed) or 30 mg twice daily for children aged 2 to 11 years. A lower dose of 15 mg twice daily is approved in the United States for small children aged six months to two years. For patients with significant renal insufficiency, the adult dose should be reduced to 60 mg once daily. It is best taken without food and specifically not with fruit juices.

There are additional nonsedating antihistamines that are available in many countries, although not in the United States:

Ebastine – Ebastine is a nonsedating antihistamine that is licensed for use in children older than 12 years of age and adults. The usual dose is 10 mg daily, but it can be doubled to 20 mg daily if needed, although not in patients with liver insufficiency. One study of patients with acute urticaria found that 20 mg of ebastine was similar in efficacy to 5 mg of levocetirizine and caused fewer adverse effects [56].

Bilastine – Bilastine is a nonsedating antihistamine with efficacy similar to cetirizine and higher than that of fexofenadine [57]. The initial dose is 20 mg daily for children older than 12 years of age and adults. Bioavailability is reduced approximately 30 percent by grapefruit juice, ketoconazole, or erythromycin, and it should not be taken with food. The drug minimally crosses the blood-brain barrier (because it is a zwitterion), does not cause somnolence, and is not affected by alcoholic beverages [58].

Rupatadine – Rupatadine antagonizes both histamine and platelet-activating factor (PAF) receptors [59]. It is licensed at a dose of 10 mg daily for patients older than 12 years of age, although it is safe in patients older than 2 years of age [60]. As is the case for bilastine, the drug should not be taken with grapefruit juice, ketoconazole, or erythromycin, but (unlike bilastine) it is not affected by food.

First-generation agents — The first-generation antihistamines include diphenhydraminechlorpheniraminehydroxyzine, and others [61]. These agents are lipophilic and readily cross the blood-brain barrier, causing sedating and anticholinergic side effects that may be dose-limiting in some patients. Significant sedation and impairment of performance (eg, fine motor skills, driving skills, and reaction times) occur in more than 20 percent of patients [62]. Anticholinergic side effects include dry mouth, diplopia, blurred vision, urinary retention, or vaginal dryness. Patients should be warned specifically about these adverse effects. Despite these adverse effects, patients at low risk of complications (eg, young, healthy patients) may find a sedating H1 antihistamine at bedtime helpful, especially when combined with a nonsedating H1 antihistamine during the day.

Some first-generation H1 antihistamines are available in parenteral preparations for use in patients in whom a more rapid onset of action is desired, such as those who have presented to the emergency department. Parenteral dosing of the first-generation agents is:

Diphenhydramine – The dose in adults is 25 to 50 mg given by slow intravenous (IV) administration or intramuscular (IM) injection every four to six hours as needed. Children may receive 0.5 to 1.25 mg/kg (up to 50 mg per dose) IV/IM every six hours as needed.


Hydroxyzine – The dose in adults is 25 to 50 mg deep IM administration in adults every four to six hours as needed. Do not administer intravenously. Children may receive 0.5 to 1 mg/kg (up to 50 mg per dose) IM every six hours as needed.

Pregnant and lactating women — Pregnant women may be treated initially with loratadine (10 mg once daily) or cetirizine (10 mg once daily). There are reassuring human data for each of these drugs in a large number of pregnant patients [63]. The first-generation agent chlorpheniramine, 4 mg orally every four to six hours, may also be safely used in pregnancy [64,65]. Safety issues surrounding the use of antihistamines in pregnancy are reviewed separately. (See «Recognition and management of allergic disease during pregnancy», section on ‘Oral antihistamines’.)

Lactating women may be treated with either cetirizine or loratadine (both are dosed at 10 mg once daily), which are minimally excreted in breast milk and should not cause sedation or poor feeding in the infant. (See «Pharmacotherapy of allergic rhinitis», section on ‘Breastfeeding women’.)

H2 antihistamines — There are very few data examining the use of H2 antihistamines for acute urticaria, but the practice is supported by one randomized trial of 91 adults presenting to an emergency department with acute allergic reactions [66]. Subjects received 50 mg IV diphenhydramine with either placebo or 50 mg IV ranitidine. At two hours, the number of patients in whom urticaria had resolved was statistically greater in the ranitidine group compared with the placebo group (25 of 29 and 13 of 24, respectively). Options for H2 antihistamines include ranitidine, nizatidinefamotidine, and cimetidine, although caution should be used with cimetidine, since it can increase levels of other drugs. (See «Antiulcer medications: Mechanism of action, pharmacology, and side effects».)

Studies of the use of H2 antihistamines in chronic urticaria are conflicting and are reviewed elsewhere [67-69]. (See «Chronic spontaneous urticaria: Standard management and patient education», section on ‘H2 antihistamines’.)

Glucocorticoids — Glucocorticoids do not appear to be necessary for isolated urticaria. However, a brief course (ie, usually a week or less) of systemic glucocorticoids may be added to antihistamine therapy for patients with prominent angioedema or if symptoms persist beyond a few days. Glucocorticoids do not inhibit mast cell degranulation but may act by suppressing a variety of contributing inflammatory mechanisms.

A small number of trials have examined the utility of glucocorticoids in the management of acute urticaria [70-72]. In the largest study, the addition of prednisone to levocetirizine did not speed resolution of acute urticaria. In this randomized trial, 100 adults presenting to the emergency department with urticaria of ≤24 hours duration without angioedema, anaphylaxis, or fever, were treated with the H1 antihistamine levocetirizine (5 mg once daily for five days) plus either placebo or prednisone (40 mg once daily for four days) and followed by phone for several days [72]. The primary endpoint was complete relief of itching two days after the start of therapy, and secondary endpoints included resolution of skin lesions, relapses, and adverse events. Most subjects had resolution of itch by day 2, with a slightly lower percentage itch-free in the prednisone group (79 versus 67 percent). Similarly, by day 2, skin lesions had resolved entirely in 78 and 70 percent of those in the placebo and prednisone groups, respectively. Thus, the addition of prednisone to levocetirizine did not speed resolution of acute urticaria. Between one-quarter and one-third of patients experienced relapse in both groups, generally within the first few days of therapy. Another smaller randomized trial found that glucocorticoids were helpful when added to antihistamines, although the antihistamine regimen used in that study (hydroxyzine 25 mg orally every four to eight hours) may have been more difficult to adhere to [70].

Our approach is to treat all patients with H1 antihistamines, adding H2 antihistamines for more severe symptoms and reserving oral glucocorticoids for those patients with prominent angioedema or persistent symptoms despite antihistamines.

The optimal agent and dose have not been determined for acute urticaria, but we typically administer:

In adults – Prednisone 30 to 60 mg daily, with tapering of the dose over five to seven days

In children – Prednisolone 0.5 to 1 mg/kg/day (maximum 60 mg daily), with tapering of the dose over five to seven days

Antihistamine therapy should be continued during and after the course of glucocorticoids because some patients experience an exacerbation as the glucocorticoids are tapered or discontinued. If symptoms do not recur over several days after stopping glucocorticoids, then antihistamines can be discontinued also. For patients whose symptoms recur when medications are discontinued, antihistamines should be reinstituted and used at the lowest effective dose. Repeated courses of glucocorticoids should be avoided, as the risks of adverse effects outweigh the benefit for most patients. (See ‘Referral’ below.)

REFERRALPatients who are suspected of having an allergic etiology causing new-onset urticaria, such as a food or medication allergy, should be referred to an allergy specialist who will equip them with epinephrine for self-injection when indicated. These issues are discussed in detail separately. (See «Anaphylaxis: Emergency treatment», section on ‘Discharge care’.)

It should be explained to patients that about one-third of cases of new-onset urticaria will prove persistent and that if they continue to have ongoing symptoms after several weeks, they should seek re-evaluation in a primary care setting. Patients with difficult-to-control symptoms may also be referred to a dermatology or allergy specialist.

SOCIETY GUIDELINE LINKSLinks to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See «Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)».)

INFORMATION FOR PATIENTSUpToDate offers two types of patient education materials, «The Basics» and «Beyond the Basics.» The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on «patient info» and the keyword(s) of interest.)

Basics topic (see «Patient education: Hives (The Basics)»)

Beyond the Basics topic (see «Patient education: Hives (urticaria) (Beyond the Basics)»)


Urticaria is common, affecting up to 20 percent of the population. Urticarial lesions are intensely pruritic, circumscribed, raised, erythematous plaques, often with central pallor. Morphology and size can vary (picture 2). Uncomplicated urticarial lesions are pruritic cutaneous plaques that develop over minutes to hours and resolve in hours without residual markings. (See ‘Clinical manifestations’ above and ‘Epidemiology’ above.)

Urticaria is classified as acute or chronic. Acute urticaria is defined as periodic outbreaks of urticarial lesions that resolve within six weeks, and two-thirds of all urticaria falls into this category. (See ‘Categorization of urticaria’ above.)

A presumptive trigger, such as common viral and bacterial infections, medications, food ingestion, or insect sting, can sometimes be identified for new-onset urticaria. (See ‘Etiologies’ above.)

Occasionally, urticaria may be the presenting feature of another systemic disorder, such as urticarial vasculitis, mastocytosis, or systemic lupus erythematous. There are specific clinical features that should prompt an evaluation for these conditions. (See ‘Systemic disorders that may include urticaria’ above.)

The diagnosis of urticaria is made clinically. A careful history should be performed to exclude possible anaphylaxis, identify a possible trigger, and determine if there are signs or symptoms to suggest urticarial vasculitis or an underlying systemic disorder. If the history does not suggest a specific trigger or underlying systemic illness, then laboratory tests are usually normal and not helpful. Some guidelines advocate obtaining a complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests at initial presentation, while others suggest testing only if symptoms persist. (See ‘Evaluation and diagnosis’ above.)

In patients with mild symptoms of new-onset urticaria, we suggest treatment with a nonsedating H1 antihistamine alone (Grade 2B). In patients at low risk of complications from anticholinergic side effects (ie, young, healthy patients), use of a sedating H1 antihistamine at bedtime and a nonsedating H1 antihistamine during the day is a reasonable alternative. (See ‘H1 antihistamines’ above.)

In patients with moderate-to-severe new-onset urticaria, we suggest adding an H2 antihistamine (Grade 2C). (See ‘H2 antihistamines’ above.)

In patients with prominent angioedema or persistent symptoms despite an H1 and H2 antihistamine, we suggest adding a brief course of oral glucocorticoids (Grade 2C). We typically administer prednisone (30 to 60 mg daily) in adults or prednisolone (0.5 to 1 mg/kg/day) in children, tapered over five to seven days. (See ‘Glucocorticoids’ above.)

Urticaria that persists beyond several weeks may represent the beginning of chronic urticaria, a disorder that is reviewed separately. (See «Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history».)

ACKNOWLEDGMENTThe editorial staff at UpToDate would like to acknowledge Clifton O Bingham, III, MD, who contributed to an earlier version of this topic review.

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Kaplan AP. Urticaria and angioedema. In: Middleton’s Allergy: Principles and practice, 7th, Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FER (Eds), Mosby, St Louis, MO 2009. Vol 2, p.1063.
  2. Sackesen C, Sekerel BE, Orhan F, et al. The etiology of different forms of urticaria in childhood. Pediatr Dermatol 2004; 21:102.
  3. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.
  4. Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694.
  5. Mortureux P, Léauté-Labrèze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998; 134:319.
  6. Plumb J, Norlin C, Young PC, Utah Pediatric Practice Based Research Network. Exposures and outcomes of children with urticaria seen in a pediatric practice-based research network: a case-control study. Arch Pediatr Adolesc Med 2001; 155:1017.
  7. Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc 2016; 37:18.
  8. Minciullo PL, Cascio A, Barberi G, Gangemi S. Urticaria and bacterial infections. Allergy Asthma Proc 2014; 35:295.
  9. Caubet JC, Kaiser L, Lemaître B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.
  10. Wu CC, Kuo HC, Yu HR, et al. Association of acute urticaria with Mycoplasma pneumoniae infection in hospitalized children. Ann Allergy Asthma Immunol 2009; 103:134.
  11. Shah KN, Honig PJ, Yan AC. «Urticaria multiforme»: a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics 2007; 119:e1177.
  12. Cribier B. Urticaria and hepatitis. Clin Rev Allergy Immunol 2006; 30:25.
  13. Friedman D, Picard-Dahan C, Grossin M, et al. Chronic urticaria revealing an HIV infection. Eur J Dermatol 1995; 5:40.
  14. Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226.
  15. Del Pozo MD, Audícana M, Diez JM, et al. Anisakis simplex, a relevant etiologic factor in acute urticaria. Allergy 1997; 52:576.
  16. Sussman GL, Beezhold DH. Allergy to latex rubber. Ann Intern Med 1995; 122:43.
  17. Wang J, Sampson HA. Food allergy. J Clin Invest 2011; 121:827.
  18. Asero R, Antonicelli L, Arena A, et al. EpidemAAITO: features of food allergy in Italian adults attending allergy clinics: a multi-centre study. Clin Exp Allergy 2009; 39:547.
  19. Bourrain JL. Occupational contact urticaria. Clin Rev Allergy Immunol 2006; 30:39.
  20. Robledo T, Cimarra M, Agustin P, Martinez-Cocera C. Adverse reaction to dextromethorphan. Allergy 2004; 59:890.
  21. Anderson BE, Miller CJ, Adams DR. Stinging nettle dermatitis. Am J Contact Dermat 2003; 14:44.
  22. Cummings AJ, Olsen M. Mechanism of action of stinging nettles. Wilderness Environ Med 2011; 22:136.
  23. Uslu S, Bulbul A, Diler B, et al. Urticaria due to Urtica dioica in a neonate. Eur J Pediatr 2011; 170:401.
  24. Oliver F, Amon EU, Breathnach A, et al. Contact urticaria due to the common stinging nettle (Urtica dioica)—histological, ultrastructural and pharmacological studies. Clin Exp Dermatol 1991; 16:1.
  25. Poole JA, Rosenwasser LJ. Chronic idiopathic urticaria exacerbated with progesterone therapy treated with novel desensitization protocol. J Allergy Clin Immunol 2004; 114:456.
  26. Shank JJ, Olney SC, Lin FL, McNamara MF. Recurrent postpartum anaphylaxis with breast-feeding. Obstet Gynecol 2009; 114:415.
  27. Bandino JP, Thoppil J, Kennedy JS, Hivnor CM. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention. Cutis 2011; 88:241.
  28. Le K, Wood G. A case of autoimmune progesterone dermatitis diagnosed by progesterone pessary. Australas J Dermatol 2011; 52:139.
  29. Bernstein IL, Bernstein DI, Lummus ZL, Bernstein JA. A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis. J Womens Health (Larchmt) 2011; 20:643.
  30. Prieto-Garcia A, Sloane DE, Gargiulo AR, et al. Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization. Fertil Steril 2011; 95:1121.e9.
  31. Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.
  32. Charlesworth EN. The spectrum of urticaria: All that urticates may not be urticaria. Immunol Allergy Clin North Am 1995; 15:641.
  33. Beltrani VS. Urticaria and angioedema. Dermatol Clin 1996; 14:171.
  34. Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma Immunol 1996; 76:484.
  35. Beltrani VS. Urticaria: reassessed. Allergy Asthma Proc 2004; 25:143.
  36. Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20:195.
  37. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66.
  38. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.
  39. Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.
  40. Grattan CE, Humphreys F, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007; 157:1116.
  41. Zuberbier T. A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines in Urticaria. World Allergy Organ J 2012; 5:S1.
  42. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64:1417.
  43. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema; part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000; 85 Suppl (6 pt 2):525.
  44. Weldon D. When your patients are itching to see you: not all hives are urticaria. Allergy Asthma Proc 2005; 26:1.
  45. Sicherer SH, Sampson HA. Auriculotemporal syndrome: a masquerader of food allergy. J Allergy Clin Immunol 1996; 97:851.
  46. Karunananthan CG, Kim HL, Kim JH. An unusual case of bilateral auriculotemporal syndrome presenting to an allergist. Ann Allergy Asthma Immunol 2002; 89:104.
  47. Beno SM, Nadel FM, Alessandrini EA. A survey of emergency department management of acute urticaria in children. Pediatr Emerg Care 2007; 23:862.
  48. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.
  49. Grattan C, Powell S, Humphreys F, British Association of Dermatologists. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144:708.
  50. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107:751.
  51. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40:72.
  52. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004; 92:635.
  53. Simons FE, Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol 2007; 18:535.
  54. Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. J Dermatolog Treat 2007; 18:23.
  55. Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W. Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Drugs 2017; 77:175.
  56. Goyal V, Gupta A, Gupta O, et al. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res 2017; 11:WC06.
  57. Jáuregui I, Bartra J, del Cuvillo A, et al. Bilastine and quality of life. J Investig Allergol Clin Immunol 2011; 21 Suppl 3:16.
  58. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10:779.
  59. González-Núñez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf 2016; 15:1439.
  60. Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol 2016; 27:55.
  61. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.
  62. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157:494.
  63. Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146.
  64. Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78:157.
  65. Schatz M, Zeiger RS. Asthma and allergy in pregnancy. Clin Perinatol 1997; 24:407.
  66. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36:462.
  67. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; :CD008596.
  68. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117:404.
  69. Guevara-Gutierrez E, Bonilla-Lopez S, Hernández-Arana S, Tlacuilo-Parra A. Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study. J Dermatolog Treat 2015; 26:548.
  70. Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med 1995; 26:547.
  71. Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol 1996; 76:295.
  72. Barniol C, Dehours E, Mallet J, et al. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. Ann Emerg Med 2017.
Topic 8101 Version 26.0